Top

Molecular Cancer

Published in:

Open Access 01-12-2020 | Renal Cancer | Research

Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA

Authors: Wei Wang, Wentao Hu, Ya Wang, Yong An, Lei Song, Panfeng Shang, Zhongjin Yue

Published in: Molecular Cancer | Issue 1/2020

Abstract

Background

Accumulating literatures have indicated that long non-coding RNAs (lncRNAs) are potential biomarkers that play key roles in tumor development and progression. Urothelial cancer associated 1 (UCA1) is a novel lncRNA that acts as a potential biomarker and is involved in the development of cancers. However, the molecular mechanism of UCA1 in renal cancer is still needed to further explore.

Methods

The relative expression level of UCA1 was determined by Real-Time qPCR in a total of 88 patients with urothelial renal cancer and in different renal cancer cell lines. Loss-of-function experiments were performed to investigate the biological roles of UCA1 and miR-182-5p on renal cancer cell proliferation, migration, apoptosis and tumorigenicity. Comprehensive transcriptional analysis, dual-luciferase reporter assay and western blot etc. were performed to explore the molecular mechanisms underlying the functions of UCA1.

Results

In this study, we found that UCA1 was significantly up-regulated in renal cancer. Moreover, increased UCA1 expression was positively correlated with differentiation and advanced TNM stage. Further experiments demonstrated that knockdown of UCA1 inhibited malignant phenotypes and Notch signal path of renal cancer cells, and miR-182-5p was reverse function as UCA1. UCA1 functioned as a miRNA sponge to positively regulate the expression of Delta-like ligand 4(DLL4) through sponging miR-182-5p and subsequently promoted malignant phenotypes of renal cancer cells, thus UCA1 playing an oncogenic role and miR-182-5p as an antioncogenic one in renal cancer pathogenesis.

Conclusion

UCA1-miR-182-5p-DLL4 axis is involved in proliferation and progression of renal cancer. Thus, this study demonstrated that UCA1 plays a critical regulatory role in renal cancer cell and UCA1 may serve as a potential diagnostic biomarker and therapeutic target of renal cancer.

Available only for authorised users

Zhou H, Tang K, Liu H, et al. Regulatory network of two tumor-suppressive noncoding RNAs interferes with the growth and metastasis of renal cell carcinoma. Mol Ther Nucleic Acids. 2019;16:554–65.CrossRefPubMedPubMedCentral

Li J, Zhuang C, Liu Y, et al. Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer. J Exp Clin Cancer Res. 2016;35(1):99.CrossRefPubMedPubMedCentral

Chen M, Zhuang C, Liu Y, et al. Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Lett. 2016;376(1):155–64.CrossRefPubMed

Li J, Zhuang C, Liu Y, et al. shRNA targeting long non-coding RNA CCAT2 controlled by tetracycline-inducible system inhibits progression of bladder cancer cells. Oncotarget. 2016;7(20):28989–97.CrossRefPubMedPubMedCentral

Zhuang C, Li J, Liu Y, et al. Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget. 2015;6(38):41194–203.CrossRefPubMedPubMedCentral

Chen M, Li J, Zhuang C. Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer. Oncotarget. 2017;8(17):28176–86.CrossRefPubMedPubMedCentral

Zhuang C, Huang X, Zhuang C, et al. Synthetic regulatory RNAs selectively suppress the progression of bladder cancer. J Exp Clin Cancer Res. 2017;36(1):151.CrossRefPubMedPubMedCentral

Gu P, Chen X, Xie R, et al. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer. Mol Cancer. 2019;18(1):109.CrossRefPubMedPubMedCentral

Zhang L, Meng X, Zhu XW, et al. Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications. Mol Cancer. 2019;18(1):102.CrossRefPubMedPubMedCentral

10.

Xu S, Wang P, Zhang J, et al. Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Mol Cancer. 2019;18(1):89.CrossRefPubMedPubMedCentral

11.

Wang X, Yang J, Guo G, et al. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway. Mol Cancer. 2019;18(1):84.CrossRefPubMedPubMedCentral

12.

Trimarchi T, Bilal E, Ntziachristos P, et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 2014;158(3):593–606.CrossRefPubMedPubMedCentral

13.

Kotzin JJ, Spencer SP, McCright SJ, et al. The long non-coding RNA Morrbid regulates Bim and short-lived myeloid cell lifespan. Nature. 2016;537(7619):239–43.CrossRefPubMedPubMedCentral

14.

Giorgetti L, Lajoie BR, Carter AC, et al. Structural organization of the inactive X chromosome in the mouse. Nature. 2016;535(7613):575–9.CrossRefPubMedPubMedCentral

15.

Sallam T, Jones MC, Gilliland T, et al. Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis. Nature. 2016;534(7605):124–8.CrossRefPubMedPubMedCentral

16.

Wang CJ, Zhu CC, Xu J, et al. The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Mol Cancer. 2019;18(1):115.CrossRefPubMedPubMedCentral

17.

Wang XS, Zhang Z, Wang HC, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human renal carcinoma. Clin Cancer Res. 2006;12(16):4851–8.CrossRefPubMed

18.

Wang F, Li X, Xie X, et al. UCA1, a non-protein-coding RNA up-regulated in renal carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008;582(13):1919–27.CrossRefPubMed

19.

Li JY, Ma X. Overexpression of long non-coding RNA UCA1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(11):7938–44.PubMedPubMedCentral

20.

Li Z, Niu H, Qin Q, et al. lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-signaling pathway in ovarian cancer. Mol Ther Nucleic Acids. 2019;17:92–101.CrossRefPubMedPubMedCentral

21.

Kong L, Wu Q, Zhao L, et al. Upregulated lncRNA-UCA1 contributes to metastasis of bile duct carcinoma through regulation of miR-122/ and activation of the ERK/MAPK signaling pathway. Cell Cycle. 2019;18(11):1212–28.CrossRefPubMedPubMedCentral

22.

Han C, Tang F, Chen J, et al. Knockdown of lncRNA-UCA1 inhibits the proliferation and migration of melanoma cells through modulating the miR-28-5p/HOXB3 axis. Exp Ther Med. 2019;17(5):4294–302.PubMedPubMedCentral

23.

Pei S, Chen J, Lu J, et al. The long noncoding RNA UCA1 negatively regulates Melanogenesis in melanocytes. J Invest Dermatol. 2019. https://doi.org/10.1016/j.jid.2019.04.029.

24.

Horita K, Kurosaki H, Nakatake M, et al. Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer. Biochem Biophys Res Commun. 2019. https://doi.org/10.1016/j.bbrc.2019.06.125.

25.

Li O, Yi W, Yang P, et al. Long non-coding RNA UCA1 promotes proliferation and invasion of intrahepatic cholangiocarcinoma cells through targeting microRNA-122. Exp Ther Med. 2019;18(1):25–32.PubMedPubMedCentral

26.

Chen Y, Fu Y, Song YF. Increased expression of lncRNA UCA1 and HULC is required for pro-inflammatory response during LPS induced sepsis in endothelial cells. Front Physiol. 2019;10:608. https://doi.org/10.3389/fphys.2019.00608.CrossRefPubMedPubMedCentral

27.

Xuan W, Yu H, Zhang X. Crosstalk between the lncRNA UCA1 and microRNAs in cancer. FEBS Lett. 2019. https://doi.org/10.1002/1873-3468.13470.

28.

He C, Lu X, Yang F, et al. LncRNA UCA1 acts as a sponge of miR-204 to up-regulate CXCR4 expression and promote prostate cancer progression. Biosci Rep. 2019;39(5):1–11. https://doi.org/10.1042/BSR20181465.

29.

Li D, Hao S. Long non-coding RNA UCA1 exerts growth modulation by miR-15a in human thyroid cancer TPC-1 cells. Artif Cells, Nanomed Biotechnol. 2019;47(1):1815–22.CrossRef

30.

Gong J, Lu X, Xu J, et al. Coexpression of UCA1 and ITGA2 in pancreatic cancer cells target the expression of miR-107 through focal adhesion pathway. J Cell Physiol. 2019;234(8):12884–96.CrossRefPubMed

31.

Sang Y, Chen B, Song X, et al. circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a Axis in breast cancer. Mol Ther. 2019. https://doi.org/10.1016/j.ymthe.2019.05.011.

32.

Cao MQ, You AB, Zhu XD, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol. 2018;11(1):12.CrossRefPubMedPubMedCentral

33.

Qin SB, Peng DY, Lu JM. MiR-182-5p inhibited oxidative stress and apoptosis triggered by oxidized low-density lipoprotein via targeting toll-like receptor 4. J Cell Physiol. 2018;233(10):6630–7.CrossRefPubMed

34.

Li Y, Chen S, Shan Z, et al. miR-182-5p improves the viability, mitosis, migration, and invasion ability of human gastric cancer cells by down-regulating RAB27A. Biosci Rep. 2017;37(3). https://doi.org/10.1042/BSR20170136.

35.

Liang Q, Chen H, Xu X. miR-182-5p attenuates high-fat -diet-induced nonalcoholic steatohepatitis in mice. Ann Hepatol. 2019;18(1):116–25 10.560.CrossRefPubMed

36.

Jia XN, Yin SD, Wei Y. MiR-182-5p inhibited proliferation and migration of ovarian cancer cells by targeting BNIP3. Eur Rev Med Pharmacol Sci. 2019;23(8):3270–6.

37.

Miles KM,Seshadri M,Ciamporcero E, et al. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts .PloS One. 2014;9(11):e112371.

38.

McClements L, Annett S, Yakkundi A, et al. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer. 2019;19(1):351.CrossRefPubMedPubMedCentral

39.

Peng J, Zhao S, Li Y, et al. DLL4 and Jagged1 are angiogenic targets of orphan nuclear receptor TR3/Nur77. Microvasc Res. 2019;124:67–75.CrossRefPubMedPubMedCentral

40.

Zheng X, Narayanan S, Sunkari VG, et al. Triggering of a Dll4-Notch1 loop impairs wound healing in diabetes. Proc Natl Acad Sci U S A. 2019;116(14):6985–94.CrossRefPubMedPubMedCentral

41.

Jaud M, Philippe C, Van Den Berghe L, et al. The PERK branch of the unfolded protein response promotes DLL4 expression by activating an alternative translation mechanism. Cancers. 2019;11(2). https://doi.org/10.3390/cancers11020142.

42.

Boardman R, Pang V, Malhi N, et al. Activation of Notch signaling by soluble Dll4 decreases vascular permeability via a cAMP/PKA-dependent pathway. Am J Physiol Heart Circ Physiol. 2019;316(5):H1065–75.CrossRefPubMedPubMedCentral

43.

Un W, Li J, Li Y, et al. Gamma-secretase inhibitor, DAPT, prevents the development of retinopathy of prematurity in a rat model by regulating the Delta-like ligand 4/Notch Homolog-1 (DLL4/Notch-1) pathway. Med Sci Monit. 2019;25:492–9.CrossRef

44.

Nakano T, Katsuki S, Chen M, et al. Uremic toxin Indoxyl sulfate promotes Proinflammatory macrophage activation via the interplay of OATP2B1 and Dll4-Notch signaling. Circulation. 2019;139(1):78–96 10.1161.CrossRefPubMedPubMedCentral

45.

Chen L, Gu T, Li B, et al. Delta-like ligand 4/DLL4 regulates the capillarization of liver sinusoidal endothelial cell and liver fibrogenesis. Null. 2019. https://doi.org/10.1016/j.bbamcr.2019.06.011.

46.

Minuzzo S, Agnusdei V, Pusceddu I, et al. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice. Carcinogenesis. 2015;36(1):115–21.CrossRefPubMed

47.

Qiu XX, Chen L, Wang CH, et al. High delta-like ligand 4 (DLL4) is correlated with peritumoral brain edema and predicts poor prognosis in primary glioblastoma. Medicine. 2014;93(8):e57.CrossRefPubMedPubMedCentral

48.

Zhuang C, Ma Q, Zhuang C, et al. LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC. FASEB J. 2019;33(10):11045–59. https://doi.org/10.1096/fj.201900078.CrossRefPubMed

49.

Gong S, Qu X, Yang S, et al. RFC3 induces epithelial-mesenchymal transition in lung adenocarcinoma cells through the Wnt/β-catenin pathway and possesses prognostic value in lung adenocarcinoma. Int J Mol Med. 2019;44(6):2276C88. https://doi.org/10.3892/ijmm.2019.4386.

50.

Fatima F. Vesiculated long non-coding RNAs: offshore packages deciphering trans-regulation between cells, cancer progression and resistance to therapies. Non-coding RNA. 2017;3(1):1–23. https://doi.org/10.3390/ncrna3010010.

Title: Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA
Authors: Wei Wang
Wentao Hu
Ya Wang
Yong An
Lei Song
Panfeng Shang
Zhongjin Yue
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Renal Cancer
Published in: Molecular Cancer / Issue 1/2020
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-020-1132-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

CircRNA inhibits DNA damage repair by interacting with host gene

The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?

The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression

PARP inhibitor resistance: the underlying mechanisms and clinical implications

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer